Delivery Order SPE2DB24D2217-SPE2DB25FJXNP
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,842.74 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML PENFILL, a pharmaceutical product. The contract is a firm fixed price delivery order with an ultimate completion date of August 4, 2025, and carries no set-aside designation, indicating it was awarded through competitive procurement. The place of performance is located in Conshohocken, Pennsylvania, the company's headquarters. This delivery order...
- The Defense Logistics Agency awarded a $17,574.35 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen vials under a firm fixed price contract type. This competitive award, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The delivery location is specified as Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,788.01 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen/ml on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $50,801.12 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of SKYRIZI 150 mg/mL pen/mL, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by July 24, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $11,830 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML, a pharmaceutical product, with performance in Conshohocken, Pennsylvania. This firm fixed price delivery order, awarded on July 30, 2025, represents a non-competitive award executed as a child contract under a larger indefinite delivery vehicle. The award is part of AmerisourceBergen's extensive pharmaceutical supply relationship with the federal government, supporting military and...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML, a pharmaceutical product, with a firm fixed price structure. The contract was awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location in Conshohocken, PA 19428. This...
- The Defense Logistics Agency awarded a delivery order valued at $37,510.45 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/mL, a pharmaceutical product. This firm fixed price contract, issued on July 21, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 comprehensive pharmaceutical supply agreement running through December 2026. The contract was competitively awarded...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML, a prescription pharmaceutical product, with a ceiling value of $26,843.24. This firm fixed-price delivery order was awarded competitively with no set-aside designation on August 5, 2025, with an ultimate completion date of August 6, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $15,346.24 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pharmaceutical product on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is performed at the contractor's Conshohocken, Pennsylvania facility. The award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a $6,119.69 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of SKYRIZI 600 mg/10 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 2, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical supply requirements. This award is issued...
- SPE2DB24D2217Indefinite Delivery Contract
- SPE2DB24D2217-SPE2DB25FJXNPDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,819.88 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML, a specialty pharmaceutical product. Issued on August 11, 2025, with an ultimate completion date of August 12, 2025, this firm fixed-price delivery order represents a competitively awarded, non-set-aside contract. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The SPE2DX vehicle serves as a comprehensive global pharmaceutical support contract enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's federal contracting demonstrates significant capability in fulfilling medical supply procurement for defense and healthcare systems, with this transaction reflecting the company's role as a critical vendor for federal pharmaceutical distribution needs serving military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.8k | 8/11/25 |